223 related articles for article (PubMed ID: 20007976)
21. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
Fessler MB
Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
[TBL] [Abstract][Full Text] [Related]
22. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.
Blaschke F; Leppanen O; Takata Y; Caglayan E; Liu J; Fishbein MC; Kappert K; Nakayama KI; Collins AR; Fleck E; Hsueh WA; Law RE; Bruemmer D
Circ Res; 2004 Dec; 95(12):e110-23. PubMed ID: 15539633
[TBL] [Abstract][Full Text] [Related]
23. Activation of the Liver X Receptor by Agonist TO901317 Improves Hepatic Insulin Resistance via Suppressing Reactive Oxygen Species and JNK Pathway.
Dong Y; Gao G; Fan H; Li S; Li X; Liu W
PLoS One; 2015; 10(4):e0124778. PubMed ID: 25909991
[TBL] [Abstract][Full Text] [Related]
24. Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats.
Harasiuk D; Baranowski M; Zabielski P; Chabowski A; Górski J
Cell Physiol Biochem; 2016; 39(1):350-9. PubMed ID: 27352290
[TBL] [Abstract][Full Text] [Related]
25. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance.
Hamlat N; Forcheron F; Negazzi S; del Carmine P; Feugier P; Bricca G; Aouichat-Bouguerra S; Beylot M
Cardiovasc Diabetol; 2009 Dec; 8():64. PubMed ID: 20030821
[TBL] [Abstract][Full Text] [Related]
26. Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J
Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881
[TBL] [Abstract][Full Text] [Related]
27. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
[TBL] [Abstract][Full Text] [Related]
28. Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation.
Yu J; Wang Q; Wang H; Lu W; Li W; Qin Z; Huang L
Vascul Pharmacol; 2014 Sep; 62(3):150-61. PubMed ID: 24892989
[TBL] [Abstract][Full Text] [Related]
29. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
[TBL] [Abstract][Full Text] [Related]
30. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR.
Cha JY; Repa JJ
J Biol Chem; 2007 Jan; 282(1):743-51. PubMed ID: 17107947
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists.
Drouineaud V; Sagot P; Garrido C; Logette E; Deckert V; Gambert P; Jimenez C; Staels B; Lagrost L; Masson D
Mol Hum Reprod; 2007 Jun; 13(6):373-9. PubMed ID: 17449538
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
33. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
[TBL] [Abstract][Full Text] [Related]
34. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.
Zeng J; Wu D; Hu H; Young JAT; Yan Z; Gao L
Hepatology; 2020 Dec; 72(6):1935-1948. PubMed ID: 32145089
[TBL] [Abstract][Full Text] [Related]
35. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Colin S; Bourguignon E; Boullay AB; Tousaint JJ; Huet S; Caira F; Staels B; Lestavel S; Lobaccaro JM; Delerive P
Endocrinology; 2008 Oct; 149(10):5128-35. PubMed ID: 18566121
[TBL] [Abstract][Full Text] [Related]
36. Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity.
Bindesbøll C; Fan Q; Nørgaard RC; MacPherson L; Ruan HB; Wu J; Pedersen TÅ; Steffensen KR; Yang X; Matthews J; Mandrup S; Nebb HI; Grønning-Wang LM
J Lipid Res; 2015 Apr; 56(4):771-85. PubMed ID: 25724563
[TBL] [Abstract][Full Text] [Related]
37. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
38. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
[TBL] [Abstract][Full Text] [Related]
39. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling.
Nolan CJ; Leahy JL; Delghingaro-Augusto V; Moibi J; Soni K; Peyot ML; Fortier M; Guay C; Lamontagne J; Barbeau A; Przybytkowski E; Joly E; Masiello P; Wang S; Mitchell GA; Prentki M
Diabetologia; 2006 Sep; 49(9):2120-30. PubMed ID: 16868750
[TBL] [Abstract][Full Text] [Related]
40. Activation of liver X receptor inhibits OCT2-mediated organic cation transport in renal proximal tubular cells.
Wongwan T; Kittayaruksakul S; Asavapanumas N; Chatsudthipong V; Soodvilai S
Pflugers Arch; 2017 Nov; 469(11):1471-1481. PubMed ID: 28741179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
